To study how neoantigen avidity impacts T cell function in adoptive cell therapy (ACT), Wittling et al. compared antitumor responses of naive transgenic pmel-1 CD8+ T cells transferred [...] bit.ly/4ptAD8y   @megen-w.bsky.social  @chrystalpaulos.bsky.social

Check out our new research on developing a model for tumor infiltrating lymphocyte (TIL) therapy for cholangiocarcinoma (CCA) by the Lesinski and Paulos Labs! @lesinskilab.bsky.social @chrystalpaulos.bsky.social academic.oup.com/jimmunol/adv...

Development of a murine tumor-infiltrating lymphocyte therapy model for cholangiocarcinoma

Abstract. Tumor-infiltrating lymphocyte (TIL) therapy is a promising approach, earning U.S. Food and Drug Administration approval in patients with anti–PD-

academic.oup.com

New Journal for ImmunoTherapy of Cancer position article and guidelines: Constructing the cure: engineering the next wave of antibody and cellular immune therapies bit.ly/3HYCbrs #JITC #ImmunoSky #MedSky

Constructing the cure: engineering the next wave of antibody and cellular immune therapies

Immuno-oncology has revolutionized cancer treatment by mobilizing the immune system to eliminate tumors. Although immune checkpoint inhibitors and T cell therapies have mediated durable responses in h...

bit.ly

🧵1/ New in @Cancer_Cell: Our lab discovered that Th17 cells must team up with B cells to eliminate tumors, and prevent it from coming back. 🔗 Read: www.cell.com/cancer-cell/... 🧬This unexpected immune duo sparks tumor immunity. 🖼️Image: See schematic Th17/B cell antitumor action!

Adoptively transferred Th17 cells cooperate with host B cells to achieve durable tumor immunity

Cole et al. report that adoptively transferred, tumor-specific Th17 cells engage host B cells and drive B cell proliferation and differentiation. These Th17 cells require B cells for sustained immunit...

cell.com

Check out our new paper in Hepatology on how myeloid cells limit immunotherapy in preclinical cholangiocarcinoma models! Disease site matters! @chrystalpaulos.bsky.social @megen-w.bsky.social @winshipcancer.emory.edu many others! pubmed.ncbi.nlm.nih.gov/40590857/

Tumor site influences efficacy of MEKi and immunotherapy combinations in pre-clinical model of cholangiocarcinoma - PubMed

These findings identify myeloid cells as key mediators of both immunotherapy resistance and toxicity in CCA, highlighting the critical importance of tumor site and use of physiologically relevant pre-...

pubmed.ncbi.nlm.nih.gov

Our findings highlight the critical role of T cell trafficking to the lymph nodes in shaping neoantigen-specific antitumor responses and offers insight for improving adoptive cellular therapies www.biorxiv.org/content/10.1...

Neoantigens drive adoptively transferred CD8 T cells to long-lived effectors mediated by lymph node trafficking

Adoptive transfer of neoantigen-reactive T lymphocytes mediates potent responses against solid tumors in patients while often limiting toxicity to normal tissues; however, the mechanisms governing the...

biorxiv.org

Inspiring (as always) @cholangiocarcinoma.bsky.social annual meeting comes to a close. Our @winshipatemory.bsky.social team returns motivated by survivors, patients and caregivers to make a difference! @megen-w.bsky.social @chrystalpaulos.bsky.social

💥Cheers to Megen Wittling @megen-w.bsky.social @winshipatemory.bsky.social for presenting exciting work on the distinct trafficking & activation patterns of adoptively transferred CD8 T cells that recognize non-mutated va mutated tumors.

Congrats to our talented grad student Megen Wittling for being award this NCI F30 grant for her work in adoptive immunotherapy today! @megen-w.bsky.social @winshipatemory.bsky.social @sitcancer.bsky.social #EmoryMSTP

🎉Congrats to Emory cancer immunologist Chrystal Paulos, PhD, (@chrystalpaulos.bsky.social) who has been named co-leader of the Cancer Immunology Research Program at Winship. ➡️ brnw.ch/21wQB3h

Cheers to @megen-w.bsky.social and #HeatherLin in the CB program @winshipatemory.bsky.social for brilliant talks on adoptive immunotherapy in yesterdays seminar series.